1085 related articles for article (PubMed ID: 24589766)
21. Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.
Atay JK; Fanikos J; Barnes GD; Ehle M; Coatney J; Piazza G; Froehlich JB; Goldhaber SZ
Am J Cardiol; 2013 Aug; 112(3):387-9. PubMed ID: 23647794
[TBL] [Abstract][Full Text] [Related]
22. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
23. Dabigatran etexilate: An alternative to warfarin for patients with nonvalvular atrial fibrillation.
Scott KA; Amirehsani KA
J Am Assoc Nurse Pract; 2015 Apr; 27(4):190-6. PubMed ID: 25066647
[TBL] [Abstract][Full Text] [Related]
24. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
25. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
Ali A; Bailey C; Abdelhafiz AH
Age Ageing; 2012 Sep; 41(5):681-4. PubMed ID: 22378612
[TBL] [Abstract][Full Text] [Related]
26. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
Hohnloser SH; Oldgren J; Yang S; Wallentin L; Ezekowitz M; Reilly P; Eikelboom J; Brueckmann M; Yusuf S; Connolly SJ
Circulation; 2012 Feb; 125(5):669-76. PubMed ID: 22215856
[TBL] [Abstract][Full Text] [Related]
27. Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice.
Kawabata M; Yokoyama Y; Sasano T; Hachiya H; Tanaka Y; Yagishita A; Sugiyama K; Nakamura T; Suzuki M; Isobe M; Hirao K
J Cardiol; 2013 Aug; 62(2):121-6. PubMed ID: 23680005
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
Kamel H; Johnston SC; Easton JD; Kim AS
Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255
[TBL] [Abstract][Full Text] [Related]
29. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
Lip GY; Clemens A; Noack H; Ferreira J; Connolly SJ; Yusuf S
Thromb Haemost; 2014 May; 111(5):933-42. PubMed ID: 24326736
[TBL] [Abstract][Full Text] [Related]
30. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Garnock-Jones KP
Am J Cardiovasc Drugs; 2011; 11(1):57-72. PubMed ID: 21265583
[TBL] [Abstract][Full Text] [Related]
31. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.
Ho CW; Ho MH; Chan PH; Hai JJ; Cheung E; Yeung CY; Lau KK; Chan KH; Lau CP; Lip GY; Leung GK; Tse HF; Siu CW
Stroke; 2015 Jan; 46(1):23-30. PubMed ID: 25406148
[TBL] [Abstract][Full Text] [Related]
32. Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.
Berger R; Salhanick SD; Chase M; Ganetsky M
Ann Emerg Med; 2013 Apr; 61(4):475-9. PubMed ID: 23522810
[TBL] [Abstract][Full Text] [Related]
33. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study.
Apostolakis S; Lane DA; Guo Y; Buller H; Lip GY
J Am Coll Cardiol; 2012 Aug; 60(9):861-7. PubMed ID: 22858389
[TBL] [Abstract][Full Text] [Related]
34. [Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].
Szapary L; Fehér G; Bosnyák E; Deli G; Csécsei P
Ideggyogy Sz; 2013 May; 66(5-6):165-74. PubMed ID: 23909016
[TBL] [Abstract][Full Text] [Related]
35. Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
Prescrire Int; 2012 Feb; 21(124):33-6. PubMed ID: 22413715
[TBL] [Abstract][Full Text] [Related]
36. Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin?
Hughes PJ; Freeman MK
Consult Pharm; 2012 Jun; 27(6):445-52. PubMed ID: 22698551
[TBL] [Abstract][Full Text] [Related]
37. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
Waks JW; Zimetbaum PJ
Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
[TBL] [Abstract][Full Text] [Related]
38. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
Paikin JS; Haroun MJ; Eikelboom JW
Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of dabigatran utilization and risk among hospitalized patients.
Sidman E; Probst LA; Darko W; Miller CD
Ann Pharmacother; 2014 Mar; 48(3):349-53. PubMed ID: 24259660
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]